Article - 08/11/2019 Nanorobots as future minimally invasive tools for the eye It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.https://www.gesundheitsindustrie-bw.de/en/article/news/Nanorobots-future-minimally-invasive-tools-for-eye
Article - 07/02/2019 Artificial intelligence in ophthalmology Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
Article - 21/08/2018 Parkinson's disease: vitamin B3 has a positive effect on nerve cells Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.https://www.gesundheitsindustrie-bw.de/en/article/news/parkinsons-disease-vitamin-b3-has-a-positive-effect-on-nerve-cells
Article - 13/06/2018 TeleDerm: Rapid help from a dermatologist via teleconsultation Some geographical locations have relatively few specialist medical practices. Getting an appointment with a specialist if you live in such areas might mean a long wait or a long journey. A study being carried out at the University of Tübingen is looking to improve this situation: the TeleDerm project involves dermatologists using telemedicine to assess skin disorders from images taken by GPs.https://www.gesundheitsindustrie-bw.de/en/article/news/telederm-rapid-help-from-a-dermatologist-via-teleconsultation
Article - 13/03/2018 “More data does not automatically imply more knowledge“ In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted. https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
Article - 14/02/2018 Animal-free diabetes research with the pancreas chip Quite a number of promising drug candidates for the treatment of diabetes are currently in the pharmaceutical pipeline, including innovative drugs that can stimulate the regeneration of insulin-producing pancreatic cells. However, they will have to be safety tested in animals. Scientists from Ulm University Hospital have now begun to develop a pancreatic chip from stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/animal-free-diabetes-research-with-the-pancreas-chip
Article - 04/09/2017 Mireca: a new drug for stopping the progression of eye diseases A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market. https://www.gesundheitsindustrie-bw.de/en/article/news/mireca-a-new-drug-for-stopping-the-progression-of-eye-diseases
Press release - 06/04/2017 Start-up in the garage – a location with prospects Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germanyhttps://www.gesundheitsindustrie-bw.de/en/article/press-release/start-up-in-the-garage-a-location-with-prospects
Article - 09/01/2017 Novaliq to develop innovative eye drop products A remedy is now available for people suffering from dry eye disease. Novaliq GmbH, a specialty pharmaceuticals company from Heidelberg, has developed a highly innovative technology platform for producing innovative drugs to eliminate common eye conditions that cause itching, burning and a feeling of pressure on the eye. The new drug delivery platform not only opens up groundbreaking new prospects for ophthalmology, but also for dermatology. https://www.gesundheitsindustrie-bw.de/en/article/news/novaliq-to-develop-innovative-eye-drop-products
Article - 08/11/2016 Towards at-home genetic testing The ability to detect a broad range of conditions and modifications in human, animal, plant and pathogen genes is highly important in the field of medicine for diagnosing diseases and starting therapy as quickly as possible. Chemists at the University of Konstanz have now developed a genetic test that does not need to be carried out in the laboratory and can be evaluated with the naked eye, similar to a pregnancy test. The test would therefore be…https://www.gesundheitsindustrie-bw.de/en/article/news/towards-at-home-genetic-testing
Article - 10/10/2016 Teva plans the large-scale production of monoclonal antibodies in Ulm Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.https://www.gesundheitsindustrie-bw.de/en/article/news/teva-plans-the-large-scale-production-of-monoclonal-antibodies-in-ulm
Article - 08/08/2016 First achromatopsia gene therapy clinical trial in Germany is going well Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now…https://www.gesundheitsindustrie-bw.de/en/article/news/first-achromatopsia-gene-therapy-clinical-trial-in-germany-is-going-well
Article - 06/06/2016 ZEISS Vision Science Lab: understanding vision Carl Zeiss AG and the University of Tübingen have been jointly running the ZEISS Vision Science Lab since 2013. This is a workgroup that is both fully integrated into research as well as delivering results for the development and improvement of products. The “Industry on Campus” professorship shows how different interests can turn out successfully for both parties involved. https://www.gesundheitsindustrie-bw.de/en/article/news/zeiss-vision-science-lab-understanding-vision
Article - 24/03/2016 Retrospective: Meet & Match "Optical Imaging: Future Trends in Medical Applications" The Meet & Match event “Optical Imaging: Future Trends in Medical Applications” – organised by BIOPRO Baden-Württemberg GmbH and the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB) in Mannheim on 9th March 2016 - attracted around 80 participants. Interesting lectures provided in-depth insights into future trends in optical imaging in medical applications.https://www.gesundheitsindustrie-bw.de/en/article/news/retrospective-meet-match-optical-imaging-future-trends-in-medical-applications
Article - 18/01/2016 New approaches in the life sciences industry: innovative strategies for courageous companies For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
Article - 16/12/2015 Small and handy – tiny LED lights can improve eye surgeons’ work A new lighting system for vitreoretinal surgery that uses small white light-emitting diode (LED) technology, promises to be safer for patients and more practical for surgeons. It will probably be three years before the idea is launched as a medical product. Prototypes need to be optimised, approved and then tested for safety and functionality at the University Eye Hospital in Frankfurt. https://www.gesundheitsindustrie-bw.de/en/article/news/small-and-handy-tiny-led-lights-can-improve-eye-surgeons-work
Article - 04/12/2015 Exploring the retinal code Dr. Philipp Berens from the Bernstein Center for Computational Neuroscience at the University of Tübingen uses computer models to study how light that enters the retina is turned into events that trigger nerve impulses. The bioinformatician has recently received the BMBF’s Bernstein Award for Computational Neuroscience.https://www.gesundheitsindustrie-bw.de/en/article/news/exploring-the-retinal-code
Article - 05/10/2015 Nanoparticles make eye drops more effective Drops are a common way of applying drugs for treating a wide of range of eye diseases. Most of us have used eye drops at least once in our lives, but we are not usually aware that even if the drops are applied correctly, only one percent of the drug reaches the eye. The rest is flushed out by eyelid movement or with tear fluid. So very high drug concentrations are needed, and the downside of this is that it can cause substantial adverse effects.…https://www.gesundheitsindustrie-bw.de/en/article/news/nanoparticles-make-eye-drops-more-effective
Article - 02/02/2015 Rentschler Biotechnologie invests in new production plant The Laupheim-based contract manufacturer Rentschler Biotechnologie GmbH is greatly expanding its production capacities. The company is investing €24 million in the construction of two 3,000 litre stainless steel bioreactors, which should be operational in early 2017 and will more than double the production capacities for cell culture-derived proteins. Rentschler also announced recently that it was adding a new 2,000 litre single-use bioreactor…https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-biotechnologie-invests-in-new-production-plant
Article - 19/01/2015 Rich in contrasts – three research months in Shanghai After graduating, Johannes Zang applied for a Baden-Württemberg Ministry of Science, Research and the Arts China Scholarship to spend three months in Shanghai before going on to do his PhD. At the Shanghai Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences, he was, amongst other things, involved in elucidating the crystal structures of proteins. He also had time to learn about the city of Shanghai, China and the Chinese…https://www.gesundheitsindustrie-bw.de/en/article/news/rich-in-contrasts-three-research-months-in-shanghai
Article - 05/01/2015 Experience report: an internship in Qingdao Nicole Kattner spent six months at the Institute of Bioenergy and Bioprocess Technology in Qingdao, a city in the coastal province of Shandong in the East China region. Nicole’s stay in China was made possible by a grant from the Baden-Württemberg Ministry of Science, Research and the Arts. Besides gaining first-hand experience in a Chinese laboratory during the week, she used public holidays and work-free weekends to travel around and learn…https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-an-internship-in-qingdao
Article - 20/10/2014 First ever eye gene therapy close to clinical testing There are many different retinal diseases simply because many different steps of the visual process can be affected. However, they all have one thing in common: correction of the relevant defective gene currently provides the only possibility of permanent cure. Prof. Dr. Mathias Seeliger and his group of researchers at the Institute of Ophthalmic Research at the University Hospital in Tübingen is specifically focused on the development of gene…https://www.gesundheitsindustrie-bw.de/en/article/news/first-ever-eye-gene-therapy-close-to-clinical-testing
Article - 07/01/2014 Distant goal: retina generation Optogenetic methods have the potential to restore the function of photoreceptors and other diseased cell types in the retina. A team from the CIN cluster of excellence at Tübingen University is exploring the basic mechanisms of how this could be achieved.https://www.gesundheitsindustrie-bw.de/en/article/news/distant-goal-retina-generation
Article - 28/11/2013 Motion sensor in the brain Researchers from the Max Planck Institute for Medical Research have shown in zebrafish that visual movement stimuli are processed in the animals’ visual system by two types of direction-sensitive neurons located in spatially separate circuits. Different directions of movement are represented in different layers.https://www.gesundheitsindustrie-bw.de/en/article/news/motion-sensor-in-the-brain
Article - 18/11/2013 Insilico Biotechnology AG: strategic orientation secures corporate growth Insilico Biotechnology AG from Stuttgart designs and optimises biotechnological processes for the chemical pharmaceutical and food industries. The company makes predictions on the behaviour of cells and organisms. This knowledge can be used to reduce the time required for the development or optimisation of biotechnological processes involving the production of drugs. The company owns a worldwide unique systems biology platform that integrates…https://www.gesundheitsindustrie-bw.de/en/article/news/insilico-biotechnology-ag-strategic-orientation-secures-corporate-growth